A detailed history of Commonwealth Equity Services, LLC transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 36,023 shares of ATOS stock, worth $37,103. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,023
Previous 26,023 38.43%
Holding current value
$37,103
Previous $31,000 77.42%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$1.09 - $1.52 $10,900 - $15,200
10,000 Added 38.43%
36,023 $55,000
Q2 2024

Jul 31, 2024

SELL
$1.03 - $2.1 $288 - $588
-280 Reduced 1.06%
26,023 $31,000
Q1 2024

Apr 29, 2024

SELL
$0.8 - $1.89 $5,633 - $13,309
-7,042 Reduced 21.12%
26,303 $47,000
Q3 2023

Oct 23, 2023

SELL
$0.74 - $1.35 $932 - $1,701
-1,260 Reduced 3.64%
33,345 $25,000
Q2 2023

Aug 10, 2023

BUY
$0.6 - $1.28 $30 - $64
50 Added 0.14%
34,605 $44,000
Q1 2023

May 11, 2023

SELL
$0.59 - $0.91 $2,212 - $3,412
-3,750 Reduced 9.79%
34,555 $25,000
Q4 2022

Feb 07, 2023

BUY
$0.5 - $1.01 $5,011 - $10,122
10,022 Added 35.43%
38,305 $20,000
Q3 2022

Nov 14, 2022

SELL
$0.82 - $1.14 $1,640 - $2,280
-2,000 Reduced 6.6%
28,283 $23,000
Q1 2022

May 04, 2022

SELL
$1.11 - $1.74 $176 - $276
-159 Reduced 0.52%
30,283 $37,000
Q4 2021

Jan 31, 2022

BUY
$1.6 - $3.27 $3,200 - $6,540
2,000 Added 7.03%
30,442 $48,000
Q3 2021

Oct 29, 2021

SELL
$2.89 - $6.4 $14,279 - $31,622
-4,941 Reduced 14.8%
28,442 $92,000
Q2 2021

Aug 11, 2021

BUY
$1.52 - $8.62 $3,040 - $17,240
2,000 Added 6.37%
33,383 $210,000
Q1 2021

May 04, 2021

BUY
$0.92 - $4.33 $28,872 - $135,888
31,383 New
31,383 $66,000

Others Institutions Holding ATOS

About ATOSSA THERAPEUTICS, INC.


  • Ticker ATOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,624,000
  • Market Cap $130M
  • Description
  • Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...
More about ATOS
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.